RTTNews | Jul 15, 2020 08:25AM EDT

08:24 Wednesday, July 15, 2020 (RTTNews.com) - Shares of Taiwan Liposome Co. Ltd. (TLC) have been trading in the range of $2.48 - $8.54 for the past one year, and closed Tuesday's trade at $6.50, up 10 cents or 1.56%. TLC is currently trading at $8.50, up $2.27 or 36.44% in the pre-market session.

The company announced that a pre-print version of a manuscript on TLC's strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine has been made publicly available.

Hydroxychloroquine or HCQ is an anti-malarial and anti-inflammatory drug that has been shown to inhibit SARS-CoV-2 infection in vitro and tested in clinical studies. However, recent clinical trials studying orally ingested HCQ have shown inconclusive results due to the extremely high doses required to achieve effective antiviral levels.

Read the original article on RTTNews ( https://www.rttnews.com/3111254/stock-alert-taiwan-liposome-shares-up-36-in-premarket.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved